Anti-Hypertensive Drugs - Cyprus

  • Cyprus
  • The projected revenue in the Anti-Hypertensive Drugs market in Cyprus is expected to reach US$3.19m in 2024.
  • This forecast indicates that the revenue will experience an annual growth rate (CAGR 2024-2029) of 0.06%, resulting in a market volume of US$3.20m by 2029.
  • When compared globally, it is worth noting that United States is expected to generate the highest revenue in this market, with an estimated amount of US$12,290.00m in 2024.
  • Despite being a small market, Cyprus has seen a growing demand for anti-hypertensive drugs due to the high prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Anti-Hypertensive Drugs market in Cyprus has been experiencing steady growth over the past few years.

Customer preferences:
There has been a growing demand for Anti-Hypertensive Drugs in Cyprus due to the increasing prevalence of hypertension among the population. The aging population and unhealthy lifestyle choices have contributed to this trend. Patients in Cyprus generally prefer to purchase Anti-Hypertensive Drugs from local pharmacies and hospitals. However, there has been a shift towards online purchases due to the convenience and accessibility offered by e-pharmacies.

Trends in the market:
The Anti-Hypertensive Drugs market in Cyprus is expected to continue its growth trajectory in the coming years. The market is being driven by the increasing prevalence of hypertension, the growing aging population, and the availability of innovative drugs. The market is also witnessing a shift towards combination therapies, which offer better efficacy and convenience to patients. Additionally, there is a growing trend towards the use of generic drugs, which are more cost-effective and offer similar therapeutic benefits as branded drugs.

Local special circumstances:
Cyprus is a small island nation with a population of approximately 1.2 million people. The healthcare sector in Cyprus is primarily funded by the government, with a significant portion of the population covered by the National Health Scheme. However, there is also a growing private healthcare sector, which is driving the demand for Anti-Hypertensive Drugs in the country. Additionally, the country's geographical location and proximity to Europe and the Middle East make it an attractive market for pharmaceutical companies.

Underlying macroeconomic factors:
The Cypriot economy has been experiencing steady growth over the past few years, with a focus on diversifying the economy and attracting foreign investment. The healthcare sector is a key focus area for the government, with significant investments being made in the sector. Additionally, the country's membership in the European Union has facilitated the import and export of pharmaceuticals, contributing to the growth of the Anti-Hypertensive Drugs market in Cyprus.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)